Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
Adv Rheumatol
;
60: 32, 2020. tab, graf
Article
in English
| LILACS
| ID: biblio-1130792
ABSTRACT
Abstract Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.(AU)
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Chloroquine
/
Rheumatic Diseases
/
Hydroxychloroquine
Limits:
Humans
Language:
English
Journal:
Adv Rheumatol
Journal subject:
Artrite
/
Reumatologia
Year:
2020
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Instituto de Ensino e Pesquisa/BR
/
Pontifícia Universidade Católica de Campinas/BR
/
UnB/BR
/
Universidade Federal de Minas Gerais/BR
/
Universidade Federal de Pernambuco/BR
/
Universidade Federal de São Paulo/BR
/
Universidade Federal do Paraná/BR
/
Universidade Federal do Rio Grande do Sul/BR
Similar
MEDLINE
...
LILACS
LIS